Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

The market expects Amgen (AMGN) to deliver a year-over-year decline in earnings on higher revenues when it reports results ...

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the ...

Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January ...

Amgen Inc (AMGN) reached a significant milestone as its stock hit a 52-week high of $346.41. This marks a notable point for the biotechnology company, reflecting a positive trend over the past year.

If you want to know who really controls Amgen Inc. (NASDAQ:AMGN), then you'll have to look at the makeup of its share ...

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results and safety concerns that raised doubts about the drug's commercial future.

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side effects.

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...